| Revenue growth | H1 revenue up 31% YoY; Q2 affected by US tariff timing issues. |
|---|---|
| Margins | EBITDA margins stabilized at 37.9% for H1; specialty segment helps. |
| Demand visibility | Strong visibility in infant nutrition; US demand recovering post-tariff clarity. |
| Management confidence | High confidence in specialty pivot and battery materials vertical expansion. |
Growth
H1 revenue grew 31% YoY to ₹302.9 Cr; EBITDA up 21% to ₹114.7 Cr. Growth is volume-driven across pharma and nutrition.
Outlook
Commissioning 51,200 MT greenfield plant in Q4 FY26; targeting 100,000 MT battery material capacity in 3-5 years.
Risks
US tariff uncertainty impacted Q2 timing; high inventory levels (195 days) and working capital intensity remain key concerns.
Last quarter's promises, checked
Delivered
- Revenue growth 10% for PFN → Delivered 31% H1 YoY (= BEAT)
- Commissioning greenfield facility → Internal validation completed (= BEAT)
- Net debt-to-equity ratio 0.04x → Maintained conservative leverage (= BEAT)
Partly delivered
- Specialty segment growth momentum → Grew 32% vs 62% previous year (= PARTIAL)
Missed
- Targeting 150-160 working capital days → Delivered 195 days (= MISS)
Earnings Call Transcript filed with NSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,164.90
- Market cap
- ₹13,157 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.0×Sector 50.4×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Investor Presentation: Key Takeaways
Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).
Sudeep Pharma Q1 FY27 Results: Net Profit ₹40.6 Cr, Up 29.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹40.6 Cr · +29.7% YoY
Sudeep Pharma Earnings Call: Key Takeaways
Sudeep Pharma reported 27.9% YoY revenue growth in FY26 to ₹642.3cr, driven by specialty ingredients and international expansion. Management is pivoting towards high-value mineral molecules and a major entry into battery materials.
Sudeep Pharma Earnings Call: Key Takeaways
Sudeep Pharma reported record FY26 revenue of ₹642.3cr, driven by the listing, the NSS acquisition, and expansion into battery materials.
Sudeep Pharma Q4 FY26 Results: Net Profit ₹48.5 Cr, Up 9.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹182.3 Cr (+15.7% YoY) and net profit of ₹48.5 Cr (+9.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹48.5 Cr · +9.7% YoY